World Journal of
Pharmaceutical and Life Sciences

ABSTRACT

Introduction: Sickle cell anemia is a hemoglobinopathy linked to a structural abnormality of the globin beta chain.
Objective: evaluate the effectiveness of Ginkgo Biloba extract in reducing sickle cell vaso-occlusive crises.
Methods: this was a descriptive and analytical observational cohort study involving two groups of sickle cell
patients: Group 1 consisting of patients on Ginko Biloba derivatives with symptomatic treatment and Group 2
benefited only from symptomatic treatment. Results: We selected 80 patients and we found a statistically
significant reduction (P = 0.03) in STA with an average of (0.15 ± 0.48) in patients in group 1 compared to those in
group 2 (0.43±0.63), a statistically significant reduction (P=0.05) in abdominal pain crisis in patients in group 1
compared to those in group 2 as well as in priapism (P=0.03) compared to group 2. A statistically significant
reduction (P = 0.05) in the number of hospitalizations in patients in group 1 compared to those in group 2.
However, the reduction in osteoarticular pain crises was not significant ( P = 0.38) with an average of (1.77 ± 1.73)
in patients in group 1 compared to those in group 2 (2.2 ± 1.68). Regarding chronic ischemic complications, aseptic
necrosis of the femoral head was less frequent (38.80%) in patients in group 1 compared to those in group 2
(56.25%). Microalbuminuria was less frequent (27.53%) in patients in group 1 compared to those in group 2
(37.50). Conclusion : With the difficulties of access to hydroxyurea in our context, Ginko Biloba Extracts can be
used in our context, as alternatives in the basic treatment of sickle cell patients.